Nutriband expanded its existing Credit Line facility to $5M to fund the continued development and regulatory submission process for the Company’s patented lead product platform, AVERSA Fentanyl, an abuse-deterrent fentanyl transdermal system. The Company is targeting FDA submission for AVERSA Fentanyl in the first half of 2024. AVERSA Fentanyl is the flagship product of the Company’s AVERSA Platform.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NTRB: